These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
90 related articles for article (PubMed ID: 8429246)
21. Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial. Sood AK; Lush R; Geisler JP; Shahin MS; Sanders L; Sullivan D; Buller RE; Sorosky JI Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6080-5. PubMed ID: 15447993 [TBL] [Abstract][Full Text] [Related]
22. [Phase II study of a continuous five-day intravenous infusion of cisplatin and etoposide with concurrent chest radiation therapy in limited stage small cell lung cancer]. Sugita T; Matsunaga K; Kobayashi H; Horikawa S; Suzuki Y; Nishiyama H; Maekawa N; Matsumoto H; Okazaki M; Katagami N Gan To Kagaku Ryoho; 1994 Oct; 21(14):2479-83. PubMed ID: 7944494 [TBL] [Abstract][Full Text] [Related]
23. Mechanism(s) of antitumor action in protracted infusion of low dose 5-fluorouracil and cisplatin in gastric carcinoma. Kim R; Tanabe K; Inoue H; Toge T Int J Oncol; 2002 Mar; 20(3):549-55. PubMed ID: 11836567 [TBL] [Abstract][Full Text] [Related]
24. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model. Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121 [TBL] [Abstract][Full Text] [Related]
25. [Chemotherapy with consecutive low-dose CDDP combined with 5-FU for gynecologic malignancies]. Shimizu Y; Hasumi K Gan To Kagaku Ryoho; 1999 Oct; 26(11):1564-74. PubMed ID: 10553414 [TBL] [Abstract][Full Text] [Related]
26. [A comparative randomized phase II study of CDDP, CDDP-carboquone (CQ) and CDDP-etoposide as second-line chemotherapy in small cell lung cancer (SCLC)]. Kobayashi K; Hino M; Kurane S; Yano T; Niitani H; Yamano Y; Hasegawa K; Tuboi E Gan To Kagaku Ryoho; 1989 Feb; 16(2):207-12. PubMed ID: 2537605 [TBL] [Abstract][Full Text] [Related]
27. [A case of poorly differentiated ovarian serous adenocarcinoma responding favorably to etoposide and cisplatin]. Sato Y; Nishida M; Inoue K; Arai Y; Sasaki J; Kubo T Gan To Kagaku Ryoho; 1996 Nov; 23(13):1847-9. PubMed ID: 8937497 [TBL] [Abstract][Full Text] [Related]
28. [Cyclic high dose CAP therapy by short-stay admission for ovarian malignancies--to increase total dose of CDDP and to improve quality of life of patients]. Ochiai K; Isonishi S; Kimura E; Yokoyama S; Sasaki H; Arihiro T; Terashima Y Nihon Sanka Fujinka Gakkai Zasshi; 1991 Jan; 43(1):19-25. PubMed ID: 1997612 [TBL] [Abstract][Full Text] [Related]
29. In vitro test-system for chemo- and thermosensitivity: an analysis of survival fractions and cell-cycle distributions in human Ewing's sarcomas as a modelfor tumors in pediatric oncology. Debes A; Rommel F; Breise M; Willers R; Göbel U; Wessalowski R Klin Padiatr; 2002; 214(4):223-9. PubMed ID: 12165906 [TBL] [Abstract][Full Text] [Related]
30. [Low-dose CDDP and 5-FU for head and neck cancer patients]. Fujii M; Kanke M; Tomita T Gan To Kagaku Ryoho; 1999 Oct; 26(11):1542-7. PubMed ID: 10553410 [TBL] [Abstract][Full Text] [Related]
31. [CDDP-ip PMUE therapy in gastric cancer cases with liver metastasis]. Hasegawa Y; Honnma S; Takanashi K; Yajima K; Nakashima Y Gan To Kagaku Ryoho; 1991 Aug; 18(11):2047-51. PubMed ID: 1908669 [TBL] [Abstract][Full Text] [Related]
32. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882. Cushing B; Giller R; Cullen JW; Marina NM; Lauer SJ; Olson TA; Rogers PC; Colombani P; Rescorla F; Billmire DF; Vinocur CD; Hawkins EP; Davis MM; Perlman EJ; London WB; Castleberry RP; ; J Clin Oncol; 2004 Jul; 22(13):2691-700. PubMed ID: 15226336 [TBL] [Abstract][Full Text] [Related]
33. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts. Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935 [TBL] [Abstract][Full Text] [Related]
34. [Combination chemotherapy with cisplatin and etoposide for cerebellar metastasis from ovarian adenocarcinoma]. Itoyama Y; Seto H; Kochi M; Kuratsu J; Korematsu K; Kitano I; Uemura S; Ushio Y No Shinkei Geka; 1991 Aug; 19(8):751-4. PubMed ID: 1896120 [TBL] [Abstract][Full Text] [Related]
35. Enhancement of antiproliferative effect of cis-diamminedichloroplatinum(II) by clomiphene and tamoxifen in human ovarian cancer cells. Kikuchi Y; Hirata J; Kita T; Imaizumi E; Tode T; Nagata I Gynecol Oncol; 1993 Jun; 49(3):365-72. PubMed ID: 8314539 [TBL] [Abstract][Full Text] [Related]
36. [-Intravenous or oral etoposide therapy of platinum refractory ovarian cancer with early recurrence. Results of a prospective randomized study-]. Kuhn W; Schmalfeldt B; Dose J; Pache L; Ulm K; Freitag K; Jänicke F; Graeff H Geburtshilfe Frauenheilkd; 1996 Feb; 56(2):105-10. PubMed ID: 8647360 [TBL] [Abstract][Full Text] [Related]
37. [Preliminary clinical evaluation of low-dose CDDP and continuous 5-FU therapy for advanced gallbladder cancer]. Tsuji A; Morita S; Horimi T; Takasaki M; Takamatsu M; Takahashi I; Shirasaka T Gan To Kagaku Ryoho; 2000 Feb; 27(2):233-7. PubMed ID: 10700893 [TBL] [Abstract][Full Text] [Related]
38. Etoposide enhances the antitumor effects of cisplatin in gastric cancer cells. Hotta T; Tanimura H; Yamaue H; Iwahashi M; Tani M; Tsunoda T; Noguchi K; Mizobata S; Arii K; Terasawa H Anticancer Res; 1997; 17(2A):885-9. PubMed ID: 9137422 [TBL] [Abstract][Full Text] [Related]
39. Continuous infusion of 5-fluorouracil with versus without low-dose, consecutive administration of cisplatin in advanced colorectal cancer. A prospective randomized phase II study. Nakata B; Sowa M; Tsuji A; Kamano T; Sasaki K; Fukunaga Y; Takahashi M; Tsujitani S; Mikami Y; Mitachi Y; Nishimura S; Araki H; Yamamitsu S; Hirakawa K; Tominaga S; Shirasaka T; Inokuchi K J Exp Clin Cancer Res; 2007 Mar; 26(1):51-60. PubMed ID: 17550132 [TBL] [Abstract][Full Text] [Related]